Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema

In a real-world setting, eyes with DME considered refractory to anti-VEGF therapy after three monthly injections which were switched to DEX implant and had better visual and anatomical outcomes at 12 months than those that continued treatment with anti-VEGF therapy.

Keywords

Anti-VEGF therapy Dexamethasone Macular edema

URI

http://hdl.handle.net/10400.22/16923

Citation

Busch, C., Zur, D., Fraser-Bell, S. et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol 55, 789–796 (2018). https://doi.org/10.1007/s00592-018-1151-x